Stato attuale e prospettive nel trattamento del carcinoma prostatico ormonoresistente

Translated title of the contribution: Actual role and perspectives in the treatment of hormone refractory prostatic cancer

Research output: Contribution to journalArticle

Abstract

Androgen deprivation therapy is the cornestone treatment for men with de novo or recurrent metastatic prostate cancer. Unfortunately, nearly all patients will develop androgen-independent ("hormone-refractory") disease that results in progressive clinical deterioration and ultimately death. Until recently, chemotherapy has been shown to palliate symptoms of hormone refractory disease but not to improve survival. Today, two large phase III trials have demonstrated an overall survival advantage for docetaxel-based regimens compared with the best standard of care. Indeed, investigations into the pathophysiology of this malignancy, novel biological agents, skeletal protectants, and radiopharmaceuticals, are expanding the clinician's armamentarium and improving patient outcomes.

Original languageItalian
Pages (from-to)195-206
Number of pages12
JournalTrends in Medicine
Volume5
Issue number3
Publication statusPublished - Jul 2005

Fingerprint

Castration-Resistant Prostatic Neoplasms
docetaxel
Androgens
Hormones
Survival
Radiopharmaceuticals
Biological Factors
Standard of Care
Prostatic Neoplasms
Drug Therapy
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Internal Medicine
  • Pharmacology (medical)

Cite this

Stato attuale e prospettive nel trattamento del carcinoma prostatico ormonoresistente. / Silvestris, Nicola; Lorusso, Vito.

In: Trends in Medicine, Vol. 5, No. 3, 07.2005, p. 195-206.

Research output: Contribution to journalArticle

@article{202bc837905b4bd8be32e38b1047a078,
title = "Stato attuale e prospettive nel trattamento del carcinoma prostatico ormonoresistente",
abstract = "Androgen deprivation therapy is the cornestone treatment for men with de novo or recurrent metastatic prostate cancer. Unfortunately, nearly all patients will develop androgen-independent ({"}hormone-refractory{"}) disease that results in progressive clinical deterioration and ultimately death. Until recently, chemotherapy has been shown to palliate symptoms of hormone refractory disease but not to improve survival. Today, two large phase III trials have demonstrated an overall survival advantage for docetaxel-based regimens compared with the best standard of care. Indeed, investigations into the pathophysiology of this malignancy, novel biological agents, skeletal protectants, and radiopharmaceuticals, are expanding the clinician's armamentarium and improving patient outcomes.",
keywords = "Chemotherapy, Hormone refractory, New agents, Prostate cancer, Radiotherapy, Treatment",
author = "Nicola Silvestris and Vito Lorusso",
year = "2005",
month = "7",
language = "Italian",
volume = "5",
pages = "195--206",
journal = "Trends in Medicine",
issn = "1594-2848",
publisher = "Pharma Project Group Edizioni Scientifiche (PPG)",
number = "3",

}

TY - JOUR

T1 - Stato attuale e prospettive nel trattamento del carcinoma prostatico ormonoresistente

AU - Silvestris, Nicola

AU - Lorusso, Vito

PY - 2005/7

Y1 - 2005/7

N2 - Androgen deprivation therapy is the cornestone treatment for men with de novo or recurrent metastatic prostate cancer. Unfortunately, nearly all patients will develop androgen-independent ("hormone-refractory") disease that results in progressive clinical deterioration and ultimately death. Until recently, chemotherapy has been shown to palliate symptoms of hormone refractory disease but not to improve survival. Today, two large phase III trials have demonstrated an overall survival advantage for docetaxel-based regimens compared with the best standard of care. Indeed, investigations into the pathophysiology of this malignancy, novel biological agents, skeletal protectants, and radiopharmaceuticals, are expanding the clinician's armamentarium and improving patient outcomes.

AB - Androgen deprivation therapy is the cornestone treatment for men with de novo or recurrent metastatic prostate cancer. Unfortunately, nearly all patients will develop androgen-independent ("hormone-refractory") disease that results in progressive clinical deterioration and ultimately death. Until recently, chemotherapy has been shown to palliate symptoms of hormone refractory disease but not to improve survival. Today, two large phase III trials have demonstrated an overall survival advantage for docetaxel-based regimens compared with the best standard of care. Indeed, investigations into the pathophysiology of this malignancy, novel biological agents, skeletal protectants, and radiopharmaceuticals, are expanding the clinician's armamentarium and improving patient outcomes.

KW - Chemotherapy

KW - Hormone refractory

KW - New agents

KW - Prostate cancer

KW - Radiotherapy

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=27844489979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27844489979&partnerID=8YFLogxK

M3 - Articolo

VL - 5

SP - 195

EP - 206

JO - Trends in Medicine

JF - Trends in Medicine

SN - 1594-2848

IS - 3

ER -